Table 3 Determinants of time to achieve PtGA ≤ 20 mm and achievement at week 100 among guselkumab-randomized patients (N = 493)

Age, years

1.00 (0.99–1.01)

-

1.00 (0.98–1.02)

-

Sex (male vs. female)

1.12 (0.89–1.41)

-

1.35 (0.91–2.00)

-

Race (White vs. Asian)

0.85 (0.36–1.97)

-

0.99 (0.24–4.03)

-

BMI, kg/m²

0.99 (0.97–1.01)

-

0.98 (0.95–1.02)

-

Guselkumab treatment (Q4W vs. Q8W)

0.96 (0.76–1.21)

-

1.00 (0.68–1.48)

-

HAQ-DI score (0–3)

-

-

-

-

PtGA VAS (0–10 cm)

0.88 (0.82–0.95)^†

0.87 (0.81–0.93)^‡

0.85 (0.75–0.96)^†

0.82 (0.74–0.92)^†

Pt Pain VAS (0–10 cm)

-

-

-

-

FACIT-Fatigue^§

1.01 (1.00–1.03)

-

1.02 (0.99–1.04)

-

History of depression (N = 8)

1.36 (0.56–3.33)

-

1.31 (0.30–5.84)

-

Suicidal ideation or non-suicidal self-injurious behaviour (N = 9)

1.06 (0.39–2.88)

-

0.57 (0.14–2.40)

-

History of fibromyalgia (N = 3)

0.71 (0.56–0.91)^†

0.70 (0.55–0.88)^†

0.59 (0.39–0.87)^†

0.56 (0.38–0.83)^†